Evidence map›Paper›PMID 38658783›Full record

ArticleBritish journal of cancer2024

Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.

Chirag Dhar, Prasanna Ramachandran, Gege Xu, Chad Pickering, Tomislav Čaval, Maurice Wong, Rachel Rice, Bo Zhou, Apoorva Srinivasan, Paul Aiyetan and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Chirag Dhar *InterVenn Biosciences, South San Francisco, CA, USA.
Prasanna Ramachandran *InterVenn Biosciences, South San Francisco, CA, USA.
Gege Xu *InterVenn Biosciences, South San Francisco, CA, USA.
Chad PickeringInterVenn Biosciences, South San Francisco, CA, USA.
Tomislav ČavalInterVenn Biosciences, South San Francisco, CA, USA.
Maurice WongInterVenn Biosciences, South San Francisco, CA, USA.
Rachel RiceInterVenn Biosciences, South San Francisco, CA, USA.
Bo ZhouInterVenn Biosciences, South San Francisco, CA, USA.
Apoorva SrinivasanInterVenn Biosciences, South San Francisco, CA, USA.
Paul AiyetanInterVenn Biosciences, South San Francisco, CA, USA.
Chih-Wei ChuInterVenn Biosciences, South San Francisco, CA, USA.
Kaitlyn MoserInterVenn Biosciences, South San Francisco, CA, USA.
Thomas J HerzogDivision of Gynecologic Oncology, University of Cincinnati Cancer Center, Cincinnati, OH, USA.
Alexander Babatunde OlawaiyeDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Francis JacobOvarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0002-0446-1942
Daniel SerieInterVenn Biosciences, South San Francisco, CA, USA.
Klaus LindpaintnerInterVenn Biosciences, South San Francisco, CA, USA.
Flavio SchwarzInterVenn Biosciences, South San Francisco, CA, USA. info@venn.bio.ORCID 0000-0002-1060-1585
InterScience (United States) · USUniversity of Basel · CHUniversity of Cincinnati · USUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a need for diagnostic tests for screening, triaging and staging of epithelial ovarian cancer (EOC). Glycoproteomics of blood samples has shown promise for biomarker discovery.

methodsWe applied glycoproteomics to serum of people with EOC or benign pelvic masses and healthy controls. A total of 653 analytes were quantified and assessed in multivariable models, which were tested in an independent cohort. Additionally, we analyzed glycosylation patterns in serum markers and in tissues.

resultsWe identified a biomarker panel that distinguished benign lesions from EOC with sensitivity and specificity of 83.5% and 90.1% in the training set, and of 86.7 and 86.7% in the test set, respectively. ROC analysis demonstrated strong performance across a range of cutoffs. Fucosylated multi-antennary glycopeptide markers were higher in late-stage than in early-stage EOC. A comparable pattern was found in late-stage EOC tissues.

conclusionsBlood glycopeptide biomarkers have the potential to distinguish benign from malignant pelvic masses, and early- from late-stage EOC. Glycosylation of circulating and tumor tissue proteins may be related. This study supports the hypothesis that blood glycoproteomic profiling can be used for EOC diagnosis and staging and it warrants further clinical evaluation.

Indexed as

Biomarkers, TumorCarcinoma, Ovarian EpithelialNeoplasm StagingOvarian NeoplasmsProteomicsAdultAgedCase-Control StudiesFemaleGlycopeptidesGlycoproteinsGlycosylationHumansMiddle AgedNeoplasms, Glandular and EpithelialSensitivity and SpecificityBiomarkers, TumorGlycopeptidesGlycoproteins

Identifiers

PMID38658783
PMCPMC11091186
OpenAlexW4395073292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.